Gedeon Richter（RGED.F）株式概要Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. 詳細RGED.F ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績2/6財務の健全性5/6配当金4/6報酬当社が推定した公正価値より36.1%で取引されている リスク分析不安定な配当実績 US市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見るRGED.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$39.0523.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture01t2016201920222025202620282031Revenue Ft1.1tEarnings Ft281.7bAdvancedSet Fair ValueView all narrativesGedeon Richter PLC 競合他社Hisamitsu PharmaceuticalSymbol: OTCPK:HTSU.YMarket cap: US$8.2bCorcept TherapeuticsSymbol: NasdaqCM:CORTMarket cap: US$6.5bIndivior PharmaceuticalsSymbol: NasdaqGS:INDVMarket cap: US$4.6bAmneal PharmaceuticalsSymbol: NasdaqGS:AMRXMarket cap: US$4.0b価格と性能株価の高値、安値、推移の概要Gedeon Richter過去の株価現在の株価Ft39.0552週高値Ft45.2852週安値Ft29.00ベータ0.321ヶ月の変化-6.49%3ヶ月変化n/a1年変化n/a3年間の変化79.05%5年間の変化33.10%IPOからの変化-78.24%最新ニュースお知らせ • Apr 08Gedeon Richter PLC announces Annual dividend, payable on June 11, 2026Gedeon Richter PLC announced Annual dividend of HUF 656.0000 per share payable on June 11, 2026, ex-date on June 03, 2026 and record date on June 04, 2026.お知らせ • Dec 12+ 5 more updatesGedeon Richter PLC, Annual General Meeting, Apr 29, 2026Gedeon Richter PLC, Annual General Meeting, Apr 29, 2026.お知らせ • Nov 28SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER).SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER) on November 27, 2025. The transaction has received approval from Antimonopoly Committee of Ukraine.お知らせ • Jul 02Gedeon Richter plc Receives European Commission Approval for Junod®? and Yaxwer®?, its Biosimilar Denosumab Products for Bone Disease and OsteoporosisGedeon Richter plc announced that the European Commission (EC) granted marketing authorization for Junod®? and Yaxwer®?, its biosimilar denosumab products. The EC decision follows the positive opinion adopted on 25 April 2025 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This approval marks a significant milestone as Richter's monoclonal antibody biosimilars receive EC authorization. Junod®? andYaxwer®? are approved for all indications of the reference medicines Prolia®? and Xgeva®? (Amgen), including the treatment of osteoporosis in postmenopausal women, prevention of skeletal-related events in patients with bone metastases from solid tumors, and treatment of unresectable giant cell tumor of bone. The EC approval is based on a comprehensive development program demonstrating biosimilarity to the reference products in terms of quality, safety, and efficacy.お知らせ • May 14Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp.Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp on May 13, 2025. As part of the transaction, Richter will become a major investor in Granata Bio and gain a seat on Granata Bio’s Board of Directors. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of unknown majority stake of GRANATA BIO Corp on May 13, 2025.お知らせ • Apr 09Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announces Annual dividend, payable on June 12, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced Annual dividend of HUF 509.0000 per share payable on June 12, 2025, ex-date on June 03, 2025 and record date on June 04, 2025.最新情報をもっと見るRecent updatesお知らせ • Apr 08Gedeon Richter PLC announces Annual dividend, payable on June 11, 2026Gedeon Richter PLC announced Annual dividend of HUF 656.0000 per share payable on June 11, 2026, ex-date on June 03, 2026 and record date on June 04, 2026.お知らせ • Dec 12+ 5 more updatesGedeon Richter PLC, Annual General Meeting, Apr 29, 2026Gedeon Richter PLC, Annual General Meeting, Apr 29, 2026.お知らせ • Nov 28SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER).SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER) on November 27, 2025. The transaction has received approval from Antimonopoly Committee of Ukraine.お知らせ • Jul 02Gedeon Richter plc Receives European Commission Approval for Junod®? and Yaxwer®?, its Biosimilar Denosumab Products for Bone Disease and OsteoporosisGedeon Richter plc announced that the European Commission (EC) granted marketing authorization for Junod®? and Yaxwer®?, its biosimilar denosumab products. The EC decision follows the positive opinion adopted on 25 April 2025 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This approval marks a significant milestone as Richter's monoclonal antibody biosimilars receive EC authorization. Junod®? andYaxwer®? are approved for all indications of the reference medicines Prolia®? and Xgeva®? (Amgen), including the treatment of osteoporosis in postmenopausal women, prevention of skeletal-related events in patients with bone metastases from solid tumors, and treatment of unresectable giant cell tumor of bone. The EC approval is based on a comprehensive development program demonstrating biosimilarity to the reference products in terms of quality, safety, and efficacy.お知らせ • May 14Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp.Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp on May 13, 2025. As part of the transaction, Richter will become a major investor in Granata Bio and gain a seat on Granata Bio’s Board of Directors. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of unknown majority stake of GRANATA BIO Corp on May 13, 2025.お知らせ • Apr 09Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announces Annual dividend, payable on June 12, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced Annual dividend of HUF 509.0000 per share payable on June 12, 2025, ex-date on June 03, 2025 and record date on June 04, 2025.お知らせ • Dec 12+ 4 more updatesRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q4, 2024 Results on Feb 28, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced that they will report Q4, 2024 results on Feb 28, 2025お知らせ • Dec 10Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Annual General Meeting, Apr 29, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Annual General Meeting, Apr 29, 2025.お知らせ • Nov 04European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of EndometriosisGedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.お知らせ • Nov 03Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®Gedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.お知らせ • Sep 17Gedeon Richter and Sumitomo Pharma Receives Positive Chmp Opinion for Ryeqo(R) for Treatment of EndometriosisGedeon Richter Plc. ('Richter') together with Sumitomo Pharma America, Inc. ('SMPA') and Sumitomo Pharma Switzerland GmbH ('SMPS') announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has adopted a positive opinion recommending the approval of a Type II Variation application for RYEQO(R) (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. The European Commission ("EC") will review the CHMP recommendation and a final decision on the Marketing Authorization Application is expected to be available in the coming months. The decision will be applicable to all member states of the European Economic Area. RYEQO(R) was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age. This application is supported by two, 24-week, multi-national clinical studies (SPIRIT 1 and SPIRIT 2) in more than 1,200 women with moderate-to-severe pain associated with endometriosis, as well as the 80-week, open-label extension study to assess longer-term use of RYEQO(R) . Together, these data represent up to two years of efficacy and safety information with RYEQO(R). Approximately 10% of women of reproductive age have endometriosis. Many women with endometriosis-associated pain are not able to manage their pain symptoms with current treatment options, underscoring the high unmet need for this disease . Endometriosis is a disease in which tissue similar to the uterine lining is found outside the uterine cavity, commonly in the lower abdomen or pelvis, on ovaries, the bladder, and the colon. This endometrial-like tissue outside the uterus results in chronic inflammation and can cause scarring and adhesions. The symptoms associated with endometriosis include painful periods and chronic pelvic pain, painful ovulation, pain during or after sexual intercourse, heavy bleeding, fatigue, and infertility. Endometriosis can also impact general physical, mental, and social well-being. RYEQO(R) (relugolix 40 mg, estradiol 1.0 mg, andnorethisterone acetate 0.5 mg) is approved for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. RYEQO(R) contains relugolix, which reduces the amount of estrogen (and other hormones) produced by ovaries, estradiol (an estrogen) which may reduce the risk of bone loss, and norethisterone acetate (a progestin) which is necessary when women with a uterus (womb) take estrogen.お知らせ • Feb 09Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired OC Distributors Ltd from Consilient Health for £32.5 million.Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired OC Distributors Ltd from Consilient Health for £32.5 million on February 7, 2023. Geoffrey Burgess, Andrew Bab, Paul Rubin and Richard Ward of Debevoise & Plimpton LLP acted as legal advisor to Gedeon Richter. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of OC Distributors Ltd from Consilient Health on February 7, 2023.お知らせ • Dec 14+ 6 more updatesRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q1, 2023 Results on May 12, 2023Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced that they will report Q1, 2023 results on May 12, 2023株主還元RGED.FUS PharmaceuticalsUS 市場7D-2.9%2.6%2.5%1Yn/a41.5%26.4%株主還元を見る業界別リターン: RGED.FがUS Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: RGED.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is RGED.F's price volatile compared to industry and market?RGED.F volatilityRGED.F Average Weekly Movement13.5%Pharmaceuticals Industry Average Movement9.9%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.1%安定した株価: RGED.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のRGED.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト190111,155Gabor Orbanwww.gedeonrichter.comリヒター・ゲデオン・ヴェギェシュゼティ・ジャール・ニルヴァーノサン・ムコド社は、世界中で医薬品の研究、開発、製造、マーケティング、販売を行っている。医薬品、卸売・小売の2つのセグメントで事業を展開。同社は、避妊薬、子宮内膜症、不妊症、更年期障害、膣感染症、子宮筋腫のための女性用ヘルスケア製品と、女性の生活を向上させるデジタル・ソリューションであるFemtechを提供している。また、慢性脳循環障害や神経因性疼痛の治療薬などの中枢神経系製品や、美容薬、抗不安薬、睡眠薬、抗てんかん薬、各種循環器系疾患の予防・治療薬なども提供している。さらに、同社は様々な健康問題に対応する様々な一般用医薬品を製造しており、その中には、心臓をサポートするパナンジン、緊急避妊ピルのエスカペールとポスティノール、下痢を治療するストプディアールとニフロキサジド、不妊症とPCOSのリヒター・サイクルバランス、創傷治療のキュリオシンなどがある；抗ウイルス・免疫賦活剤のGroprinosin、妊娠サプリメントのFolik、腰痛・関節痛のMoilec、鎮痛錠剤のFasconal、アレルギーのLordestin、マグネシウムサプリメントのMagnezin、抗炎症・抗リウマチクリームのAflamil、咽頭痛・局所麻酔薬のOralsept。さらに、財務・会計、社会・福祉、ポートフォリオ・プロジェクト管理、ケータリング、運送、エンジニアリング、品質管理、トレーディング、資産管理、バイオテクノロジーなどのサービスも提供している。リヒテル・ゲデオン・ヴェギェシュゼティ・ニャール・ニルヴァーノサン・ムコド社は1901年設立で、ハンガリーのブダペストに本社を置く。もっと見るGedeon Richter PLC 基礎のまとめGedeon Richter の収益と売上を時価総額と比較するとどうか。RGED.F 基礎統計学時価総額US$7.26b収益（TTM）US$749.75m売上高(TTM)US$3.02b9.7xPER（株価収益率2.4xP/SレシオRGED.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計RGED.F 損益計算書（TTM）収益Ft925.14b売上原価Ft302.61b売上総利益Ft622.53bその他の費用Ft393.05b収益Ft229.48b直近の収益報告Mar 31, 2026次回決算日Aug 07, 2026一株当たり利益（EPS）1.26kグロス・マージン67.29%純利益率24.80%有利子負債／自己資本比率5.5%RGED.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金4.2%現在の配当利回り42%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 14:44終値2026/05/26 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Gedeon Richter PLC 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20 アナリスト機関Simon MatherBarclaysPatrick Andrew WoodBofA Global ResearchGabor BuktaConCorde Securities Ltd.17 その他のアナリストを表示
お知らせ • Apr 08Gedeon Richter PLC announces Annual dividend, payable on June 11, 2026Gedeon Richter PLC announced Annual dividend of HUF 656.0000 per share payable on June 11, 2026, ex-date on June 03, 2026 and record date on June 04, 2026.
お知らせ • Dec 12+ 5 more updatesGedeon Richter PLC, Annual General Meeting, Apr 29, 2026Gedeon Richter PLC, Annual General Meeting, Apr 29, 2026.
お知らせ • Nov 28SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER).SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER) on November 27, 2025. The transaction has received approval from Antimonopoly Committee of Ukraine.
お知らせ • Jul 02Gedeon Richter plc Receives European Commission Approval for Junod®? and Yaxwer®?, its Biosimilar Denosumab Products for Bone Disease and OsteoporosisGedeon Richter plc announced that the European Commission (EC) granted marketing authorization for Junod®? and Yaxwer®?, its biosimilar denosumab products. The EC decision follows the positive opinion adopted on 25 April 2025 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This approval marks a significant milestone as Richter's monoclonal antibody biosimilars receive EC authorization. Junod®? andYaxwer®? are approved for all indications of the reference medicines Prolia®? and Xgeva®? (Amgen), including the treatment of osteoporosis in postmenopausal women, prevention of skeletal-related events in patients with bone metastases from solid tumors, and treatment of unresectable giant cell tumor of bone. The EC approval is based on a comprehensive development program demonstrating biosimilarity to the reference products in terms of quality, safety, and efficacy.
お知らせ • May 14Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp.Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp on May 13, 2025. As part of the transaction, Richter will become a major investor in Granata Bio and gain a seat on Granata Bio’s Board of Directors. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of unknown majority stake of GRANATA BIO Corp on May 13, 2025.
お知らせ • Apr 09Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announces Annual dividend, payable on June 12, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced Annual dividend of HUF 509.0000 per share payable on June 12, 2025, ex-date on June 03, 2025 and record date on June 04, 2025.
お知らせ • Apr 08Gedeon Richter PLC announces Annual dividend, payable on June 11, 2026Gedeon Richter PLC announced Annual dividend of HUF 656.0000 per share payable on June 11, 2026, ex-date on June 03, 2026 and record date on June 04, 2026.
お知らせ • Dec 12+ 5 more updatesGedeon Richter PLC, Annual General Meeting, Apr 29, 2026Gedeon Richter PLC, Annual General Meeting, Apr 29, 2026.
お知らせ • Nov 28SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER).SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER) on November 27, 2025. The transaction has received approval from Antimonopoly Committee of Ukraine.
お知らせ • Jul 02Gedeon Richter plc Receives European Commission Approval for Junod®? and Yaxwer®?, its Biosimilar Denosumab Products for Bone Disease and OsteoporosisGedeon Richter plc announced that the European Commission (EC) granted marketing authorization for Junod®? and Yaxwer®?, its biosimilar denosumab products. The EC decision follows the positive opinion adopted on 25 April 2025 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This approval marks a significant milestone as Richter's monoclonal antibody biosimilars receive EC authorization. Junod®? andYaxwer®? are approved for all indications of the reference medicines Prolia®? and Xgeva®? (Amgen), including the treatment of osteoporosis in postmenopausal women, prevention of skeletal-related events in patients with bone metastases from solid tumors, and treatment of unresectable giant cell tumor of bone. The EC approval is based on a comprehensive development program demonstrating biosimilarity to the reference products in terms of quality, safety, and efficacy.
お知らせ • May 14Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp.Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp on May 13, 2025. As part of the transaction, Richter will become a major investor in Granata Bio and gain a seat on Granata Bio’s Board of Directors. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of unknown majority stake of GRANATA BIO Corp on May 13, 2025.
お知らせ • Apr 09Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announces Annual dividend, payable on June 12, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced Annual dividend of HUF 509.0000 per share payable on June 12, 2025, ex-date on June 03, 2025 and record date on June 04, 2025.
お知らせ • Dec 12+ 4 more updatesRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q4, 2024 Results on Feb 28, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced that they will report Q4, 2024 results on Feb 28, 2025
お知らせ • Dec 10Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Annual General Meeting, Apr 29, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Annual General Meeting, Apr 29, 2025.
お知らせ • Nov 04European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of EndometriosisGedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.
お知らせ • Nov 03Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®Gedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.
お知らせ • Sep 17Gedeon Richter and Sumitomo Pharma Receives Positive Chmp Opinion for Ryeqo(R) for Treatment of EndometriosisGedeon Richter Plc. ('Richter') together with Sumitomo Pharma America, Inc. ('SMPA') and Sumitomo Pharma Switzerland GmbH ('SMPS') announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has adopted a positive opinion recommending the approval of a Type II Variation application for RYEQO(R) (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. The European Commission ("EC") will review the CHMP recommendation and a final decision on the Marketing Authorization Application is expected to be available in the coming months. The decision will be applicable to all member states of the European Economic Area. RYEQO(R) was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age. This application is supported by two, 24-week, multi-national clinical studies (SPIRIT 1 and SPIRIT 2) in more than 1,200 women with moderate-to-severe pain associated with endometriosis, as well as the 80-week, open-label extension study to assess longer-term use of RYEQO(R) . Together, these data represent up to two years of efficacy and safety information with RYEQO(R). Approximately 10% of women of reproductive age have endometriosis. Many women with endometriosis-associated pain are not able to manage their pain symptoms with current treatment options, underscoring the high unmet need for this disease . Endometriosis is a disease in which tissue similar to the uterine lining is found outside the uterine cavity, commonly in the lower abdomen or pelvis, on ovaries, the bladder, and the colon. This endometrial-like tissue outside the uterus results in chronic inflammation and can cause scarring and adhesions. The symptoms associated with endometriosis include painful periods and chronic pelvic pain, painful ovulation, pain during or after sexual intercourse, heavy bleeding, fatigue, and infertility. Endometriosis can also impact general physical, mental, and social well-being. RYEQO(R) (relugolix 40 mg, estradiol 1.0 mg, andnorethisterone acetate 0.5 mg) is approved for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. RYEQO(R) contains relugolix, which reduces the amount of estrogen (and other hormones) produced by ovaries, estradiol (an estrogen) which may reduce the risk of bone loss, and norethisterone acetate (a progestin) which is necessary when women with a uterus (womb) take estrogen.
お知らせ • Feb 09Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired OC Distributors Ltd from Consilient Health for £32.5 million.Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired OC Distributors Ltd from Consilient Health for £32.5 million on February 7, 2023. Geoffrey Burgess, Andrew Bab, Paul Rubin and Richard Ward of Debevoise & Plimpton LLP acted as legal advisor to Gedeon Richter. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of OC Distributors Ltd from Consilient Health on February 7, 2023.
お知らせ • Dec 14+ 6 more updatesRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q1, 2023 Results on May 12, 2023Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced that they will report Q1, 2023 results on May 12, 2023
